| Literature DB >> 31666827 |
Manish Kumar Verma1, Anoop Jaiswal2, Preeti Sharma3, Pradeep Kumar3, Anand Narayan Singh1.
Abstract
Concurrent with the misbalance of oxidizing agents and antioxidants, high blood pressure is a major physical burden condition in the current scenario. Tumor necrosis factor-α (TNF-α) plays a vital role in the pathogenesis of hypertension. Tumor necrosis factor-α, inhibitor improves clinical symptoms however their outcome on high blood pressure has not been investigated. We investigated the inflammatory marker TNF-α, malondialdehyde (MDA) and ferric reducing antioxidant power (FRAP) in hypertensive patients. We measured randomly blood pressure using an ambulatory observe in hypertensive patients, measured systolic BP X 140 mmHg and/or diastolic BP X 90 mmHg were considered hypertensive. Total 60 cases were considered in the study that involves 30 hypertensive patients and 30 normal control. Measurements of serum concentrations of TNF-α, MDA, FRAP in hypertension patients was done in both the groups. Serum TNF-α was found to be remarkably increased in study subjects as compared to normal group (r=0.32, p<0.0001*). Serum MDA was also raised in hypertensive as compared to control (r=0.99**, p<0.0001*). While Serum FRAP was found to be decreased in hypertensive group in comparison to healthy control (r=0.23, p<0.0001*). It is concluded that high blood pressure leads to generation of oxidative stress with remarkable elevation of TNF-α and malondialdehyde levels. While reduced FRAP indicates its probable role in lipid peroxidation and in the pathogenesis of hypertension. ©Carol Davila University Press.Entities:
Keywords: FRAP – Ferric reducing antioxidant power; MDA – Malondialdehyde; ML – Milliliter; NO – Nitric oxide; ROS – Reactive Oxygen Species; TNF-α – Tumor Necrosis Factor; biomarker; blood pressure; hypertension; reactive oxygen species
Mesh:
Substances:
Year: 2019 PMID: 31666827 PMCID: PMC6814874 DOI: 10.25122/jml-2019-0031
Source DB: PubMed Journal: J Med Life ISSN: 1844-122X
Frequency distribution among male and female in normotensive persons
| Gender | Frequency (%) | Valid Percent |
|---|---|---|
| Hypertension Patients (n=30) | ||
| Female | 11(36.7) | 36.7 |
| Male | 19(63.3) | 63.3 |
| Total | 30(100.0) | 100.0 |
| Normotensive Patients (n=30) | ||
| Female | 12(40) | 40 |
| Male | 19(60) | 60 |
| Total | 30(100.0) | 100.0 |
Chi square test
Clinical characteristics of normotensive subjects and hypertensive patients participating in the study.
| Parameter | Hypertension mean±SD (n=30) | Normotensive mean±SD (n=30) | p-Value | t-Value |
|---|---|---|---|---|
| Age | 54.73±11.8 | 51.23±13.2 | 0.2834 | 1.0827 |
| MDA | 4.77±0.47 | 1.89±0.48 | 0.0001** | 23.4812 |
| FRAP | 314.7±4.18 | 432.34±4.83 | 0.0001** | 100.8739 |
| TNF-α | 5.01±1.11 | 2.12±1.35 | 0.0001** | 9.0569 |
| FBS | 104.87±7.53 | 98.33±8.35 | 0.0023* | 3.1858 |
| SBP | 161.51±8.57 | 122.01±6.55 | 0.0001** | 20.0881 |
| DBP | 100.53±8.42 | 84.11±3.10 | 0.0001** | 12.4653 |
Unpaired t-test, **Statistically highly significant, *Significant.
Pearson correlation coefficient among the biochemical parameters in cases
| FRAP (μmol/l) | TNF-α (ng/mL) | FBS (mg/dl) | SBP (mmHg) | DBP (mmHg) | ||
|---|---|---|---|---|---|---|
| MDA (µmoll) | Pearson correlation | 0.118 | 0.164 | 0.139 | –0.073 | 0.148 |
| Sig. (2-tailed) | 0.536 | 0.385 | 0.465 | 0.700 | 0.434 | |
| n | 30 | 30 | 30 | 30 | 30 | |
| FRAP (μmol/l) | Pearson correlation | –0.040 | 0.048 | –0.173 | 0.189 | |
| Sig. (2-tailed) | 0.834 | 0.801 | 0.360 | 0.318 | ||
| n | 30 | 30 | 30 | 30 | ||
| TNF-α (ng/mL) | Pearson correlation | –0.194 | –0.092 | 0.020 | ||
| Sig. (2-tailed) | 0.303 | 0.629 | 0.917 | |||
| n | 30 | 30 | 30 | |||
| FBS (mg/dl) | Pearson correlation | -0.075 | –0.150 | |||
| Sig. (2-tailed) | 0.695 | 0.428 | ||||
| n | 30 | 30 | ||||
| SBP (mmHg) | Pearson correlation | 0.013 | ||||
| Sig. (2-tailed) | 0.944 | |||||
| n | 30 | |||||
Pearson correlation coefficient among the parameters in controls
| FRAP (μmol/l) | TNF-α (ng/mL) | FBS (mg/dl) | SBP (mmHg) | DBP (mmHg) | ||
|---|---|---|---|---|---|---|
| MDA (µmol/l) | Pearson correlation | 0.329 | –0.443 | –0.111 | 0.331 | –0.038 |
| Sig. (2-tailed) | 0.076 | 0.014 | 0.559 | 0.074 | 0.842 | |
| n | 30 | 30 | 30 | 30 | 30 | |
| FRAP (μmol/l) | Pearson correlation | –0.348 | 0.184 | 0.204 | –0.254 | |
| Sig. (2-tailed) | 0.060 | 0.331 | 0.279 | 0.176 | ||
| n | 30 | 30 | 30 | 30 | ||
| TNF-α (ng/ml) | Pearson correlation | –0.142 | –0.161 | –0.012 | ||
| Sig. (2-tailed) | 0.453 | 0.396 | 0.948 | |||
| n | 30 | 30 | 30 | |||
| FBS (mg/dl) | Pearson correlation | 0.070 | 0.286 | |||
| Sig. (2-tailed) | 0.713 | 0.126 | ||||
| n | 30 | 30 | ||||
| SBP (mmHg) | Pearson correlation | 0.195 | ||||
| Sig. (2-tailed) | 0.302 | |||||
| n | 30 | |||||